Pre-Exposure Prophylaxis (PrEP)
Pre-exposure prophylaxis (or PrEP) is medicine taken to prevent getting HIV. PrEP is highly effective for preventing HIV when taken as prescribed.
- PrEP reduces the risk of getting HIV from sex by about 99%.
- PrEP reduces the risk of getting HIV from injection drug use by at least 74%.
PrEP is less effective when not taken as prescribed. Since PrEP only protects against HIV, condom use is still important for the protection against other STDs. Condom use is also important to help prevent HIV if PrEP is not taken as prescribed.
Resources for Providers
Resources for Consumers
- PrEP Basics
- Let’s Stop HIV Together Campaign: Prevention Resources
- Pocket Guide: PrEP [PDF – 418 KB] and Folding Instructions [PDF – 1 MB]
- Info Sheet: PrEP 101 [PDF – 226 KB]
- Video: PrEP
- Flyer: Paying for PrEP [PDF – 441 KB]
- Fact Sheet: Acute HIV Infection: Information about Acute HIV Infection and PrEP [PDF – 221 KB]
- Fact Sheet: Truvada Medication Information Sheet for Patients [PDF – 187 KB]
- Brochure: Now’s the Time to Find Out About PrEP [PDF – 3.9 MB]
- Brochure: PrEP Medication Guide – Reduce Your Risk of Getting HIV [PDF – 2.6 MB]
- Brochure: PrEP Is for Women [PDF – 3 MB]
- Video: Are You Ready for PrEP?
PrEP Clinical Trials
- iPrEX: Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363(27):2587-99.
- TDF2: Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367(5):423-34.
- Partners PrEP: Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367(5):399-410.
- Bangkok Tenofovir Study: Choopanya K, Martin M, Suntharasamai P, et al; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381(9883):2083-90.